Neurogene reports Q1 net loss $30.9M; ~90% dosed in Rett gene therapy trial, cash runway to Q1 2028

Neurogene Inc.

• Net loss $30.9M for Q1 2026 vs $22.6M in Q1 2025; R&D expenses $25.2M driven by NGN-401 trial and CMC costs.
• ~90% of participants dosed in Embolden registrational trial; on track to complete dosing in Q2 2026; no HLH at 1E15 vg dose.
• Cash, equivalents and short-term investments $243.2M as of March 31, 2026; expected to fund operations through Q1 2028.
• Appointed Christy Shafer as Chief Commercial Officer; Christine Mikail added to Board of Directors.
• Interim Phase 1/2 data with ≥12 months follow-up for all 10 participants expected mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.